中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HDV感染的流行病学、发病机制及诊疗进展

王宇 陈小华 赵志敏 黄恺 刘成海

陈斌, 张涛, 朱文芳, 彭杰, 张茜茜, 黎运芳, 丁秀丽. 清温并用法对慢加急性肝衰竭大鼠调节性T淋巴细胞/辅助性T淋巴细胞17表达的影响[J]. 临床肝胆病杂志, 2018, 34(12): 2642-2647. DOI: 10.3969/j.issn.1001-5256.2018.12.026.
引用本文: 陈斌, 张涛, 朱文芳, 彭杰, 张茜茜, 黎运芳, 丁秀丽. 清温并用法对慢加急性肝衰竭大鼠调节性T淋巴细胞/辅助性T淋巴细胞17表达的影响[J]. 临床肝胆病杂志, 2018, 34(12): 2642-2647. DOI: 10.3969/j.issn.1001-5256.2018.12.026.
Chen Bin, Zhang Tao, Zhu WenFang, Peng Jie, Zhang QianQian, Li YunFang, Ding XiuLi. Effect of the warming and heat-clearing method on the percentage of regulatory T lymphocytes/T helper 17 cells in rats with acute-on-chronic liver failure[J]. J Clin Hepatol, 2018, 34(12): 2642-2647. DOI: 10.3969/j.issn.1001-5256.2018.12.026.
Citation: Chen Bin, Zhang Tao, Zhu WenFang, Peng Jie, Zhang QianQian, Li YunFang, Ding XiuLi. Effect of the warming and heat-clearing method on the percentage of regulatory T lymphocytes/T helper 17 cells in rats with acute-on-chronic liver failure[J]. J Clin Hepatol, 2018, 34(12): 2642-2647. DOI: 10.3969/j.issn.1001-5256.2018.12.026.

HDV感染的流行病学、发病机制及诊疗进展

DOI: 10.3969/j.issn.1001-5256.2019.03.040
详细信息
  • 中图分类号: R512.6;R181.3

Research advances in epidemiology, pathogenesis, and diagnosis and treatment of hepatitis D virus infection

  • 摘要: HBV/HDV合并感染可导致肝病进展加速,但由于HDV RNA等检测方法学尚存在一定局限,HDV的流行病学尚不十分清楚; HDV导致HBV/HDV共感染者的发病机制及其治疗措施也需要进一步探讨。通过回顾我国以及其他国家HDV流行病学特征、HDV特异性免疫与基因型发病机制,并总结HDV的检测方法及治疗方法,分析表明现有HDV感染的检测方法敏感度、特异度低,也无标准化检测方法;探究新的HDV感染检测方法,将有助于研发新型有效抗的HDV药物,对提高HDV感染的疗效具有重要意义。

     

  • [1] CIANCIO A, RIZZETTO M. Chronic hepatitis D at a standstill:Where do we go from here?[J]. Nat Rev Gastroenterol Hep-atol, 2014, 11 (1) :68-71.
    [2] BGUELIN C, MORADPOUR D, SAHLI R, et al. Hepatitis del-ta-associated mortality in HIV/HBV-coinfected patients[J].J Hepatol, 2017, 66 (2) :112.
    [3] ROMEO R, DEL NE, RUMI M, et al. A 28-year study of thecourse of hepatitis Deltainfection:A risk factor for cirrhosis andhepatocellular carcinoma[J]. Gastroenterol Hepatol, 2009, 136 (5) :1629-1638.
    [4] WELLER ML, GARDENER MR, BOGUS ZC, et al. Hepatitisdelta virus detected in salivary glands of Sjgren's syndromepatients and recapitulates a Sjgren's syndrome-like pheno-type in vivo[J]. Pathog Immun, 2016, 1 (1) :12-40.
    [5] FARCI P. Delta hepatitis:An update[J]. J Hepatol, 2003, 39 (1) :212-219.
    [6] FLODGREN E, BENGTSSON S, KNUTSSON M, et al. Recenthigh incidence of fulminant hepatitis in Samara, Russia:Mo-lecular analysis of prevailing hepatitis B and D virus strains[J]. J Clin Microbiol, 2000, 38 (9) :3311-3316.
    [7] RIZZETTO M. Hepatitis D Virus:Introduction and epidemiolo-gy[J]. Cold Spring Harb Perspect Med, 2015, 5:a021576.
    [8] HOLMBERG S, WARD J. Hepatitis delta:Seek and ye shallfind[J]. J Infect Dis, 2010, 202 (6) :822-824.
    [9] WEDEMEYER H. Re-emerging interest in hepatitis delta:New in-sights into the dynamic interplay between HBV and HDV[J]. JHepatol, 2010, 52 (5) :627-629.
    [10] SMEDILE A, LAVARINI C, FARCI P, et al. Epidemiologic pat-terns of infection with the hepatitis B virus-associated delta a-gent in Italy[J]. Am J Epidemiol, 1983, 117 (2) :223-229.
    [11] SHADUR B, MACLACHLAN J, COWIE B. Hepatitis D virus inVictoria 2000-2009[J]. Intern Med J, 2013, 43 (10) :1081-1087.
    [12] GISH RG, YI DH, KANE S, et al. Coinfection with hepatitis Band D:Epidemiology, prevalence and disease in patients inNorthern California[J]. J Gastroenterol Hepatol, 2013, 28 (9) :1521-1525.
    [13] ABBAS Z, JAFRI W, RAZA S. Hepatitis D:Scenario in the A-sia-Pacific region[J]. World J Gastroenterol, 2010, 16 (5) :554-562.
    [14] SHEN L, GU Y, SUN L, et al. Development of a hepatitis del-ta virus antibody assay for study of the prevalence of HDV a-mong individuals infected with hepatitis B virus in China[J]. JMed Virol, 2012, 84 (3) :445-449.
    [15] LIAO B, ZHANG F, LIN S, et al. Epidemiological, clinical andhistological characteristics of HBV/HDV co-infection:A retro-spective cross-sectional study in Guangdong, China[J].PLo S One, 2014, 9 (12) :e115888.
    [16] RIZZETTO M, HOYER B, CANESE MG, et al. Delta agent:Association of delta antigen with hepatitis B surface antigenand RNA in serum of deltainfected chimpanzees[J]. Proc NatlAcad Sci U S A, 1980, 77 (10) :6124-6128.
    [17] BONINO F, HEERMANN KH, RIZZETTO M, et al. Hepatitis deltavirus:Protein composition of delta antigen and its hepatitis B virus-derived envelope[J]. J Virol, 1986, 58 (3) :945-950.
    [18] GUDIMA S, CHANG J, MORALEDA G, et al. Parameters ofhuman hepatitis delta virus genome replication:The quantity, quality, and intracellular distribution of viral proteins and RNA[J]. J Virol, 2002, 76 (8) :3709-3719.
    [19] LEMPP FA, URBAN S. Hepatitis Delta virus:Replication strat-egy and upcoming therapeutic options for a neglected humanpathogen[J]. Viruses, 2017, 9 (7) :172.
    [20] GIERSCH K, ALLWEISS L, VOLZ T, et al. Hepatitis delta co-infection in humanized mice leads to pronounced inductionofinnate immune responses in comparison to HBV mono-infec-tion[J]. J Hepatol, 2015, 63 (2) :346-353.
    [21] CHAO M, HSIEH SY, TAYLOR J. Role of two forms of hepati-tis delta virus antigen:Evidence for a mechanism of selflimitinggenome replication[J]. J Virol, 1990, 64 (3) :5066-5069.
    [22] GLENN JS, WATSON JA, HAVEL CM, et al. Identification of aprenylation site in delta virus large antigen[J]. Science, 1992, 256 (5061) :1331-1333.
    [23] KUO MY, GOLDBERG J, COATES L, et al. Molecular cloningof hepatitis delta virus RNA from an infected woodchuck liver:Sequence, structure, and applications[J]. J Virol, 1988, 62 (6) :1855-1861.
    [24] SUREAU C, NEGRO F. The hepatitis delta virus:Replicationand pathogenesis[J]. J Hepatol, 2016, 64 (1 Suppl) :s102.
    [25] MEI C. RNA recombination in hepatitis delta virus:Implicationsregarding the abilities of mammalian RNA polymerases[J]. Vi-rus Res, 2007, 127 (2) :208-215.
    [26] HUGHES SA, WEDEMEYER H, HRRISON PM. Hepatitis deltavirus[J]. The Lancet, 378 (9785) :73-85.
    [27] TABAKMAN SM, LAU L, ROBINSON JT, et al. Plasmonic substratesfor multiplexed protein microarrays with femtomolar sensitivity andbroad dynamic range[J]. Nat Commun, 2011, 2 (9) :466.
    [28] REGEV A, SCHIFF ER. Clinical features of hepatitis[J]. Se-min Liver Dis, 2012, 32 (3) :228-236.
    [29] TAYLOR JM. Viral hepatitis D[J]. Springer US, 2011, 5:589-595.
    [30] WRANKE A, HEIDRICH B, ERNST S, et al. Anti-HDV IgM asa marker of disease activity in hepatitis delta[J]. PLo S One, 2014, 9 (7) :e101002.
    [31] PASCARELLA S, NEGRO F. Hepatitis D virus:An update[J].Liver Int, 2015, 31 (1) :7-21.
    [32] GRIPPON P, RIBIERE O, CADRANEL JF, et al. Long-termdelta antigenaemia without appearance of delta antibody in twoimmunodeficient patients[J]. Lancet, 1987, 329 (8540) :1031-1031.
    [33] KODANI M, MARTIN A, MIXSON-HAYDEN T, et al. One-step real-time PCR assay for detection and quantitation ofhepatitis D virus RNA[J]. J Virol Methods, 2013, 193 (2) :531-535.
    [34] SMEDILE A, NIRO MG, RIZZETTO M. Detection of serum HDV-RNA by RT-PCR[J]. Methods Mol Med, 2004, 95 (7) :85-93.
    [35] WANG Y, GLENN JS, WINTERS MA, et al. A new dual-targetingreal-time RT-PCR assay for hepatitis D virus RNA detection[J].Diagn Microbiol Infect Dis, 2018, 92 (2) :112-117.
    [36] YAMASHIRO T, NAGAYAMA K, ENOMOTO N, et al. Quantifica-tion of the levelof hepatitis delta virus RNA in serum, by real-timepolymerase chain reaction, and its possible correlation with theclinical stage of liver disease[J]. J Infect Dis, 2004, 189 (7) :1151-1157.
    [37] ROMEO R, FOGLIENI B, CASAZZA G, et al. High serum levels ofHDV RNA are predictors of cirrhosis and liver cancer in patientswith chronic hepatitis delta[J]. PLo S One, 2014, 9 (3) :e92062.
    [38] BRICHLER S, LE GAL F, BUTT A, et al. Commercial real-timereverse transcriptase PCR assays can underestimate or fail toquantify hepatitis delta virus viremia[J]. Clin Gastroenterol Hepa-tol, 2013, 11 (6) :734-740.
    [39] BATTEGAY M, SIMPSON LH, HOOFNAGLE JH, et al. Eliminationof hepatitis delta virus infection after loss of hepatitis B surface an-tigen in patients with chronic delta hepatitis[J]. J Med Virol, 1994, 44 (4) :389-392.
    [40] LUTTERKORT GL, WRANKE A, HENGST J, et al. Viral domi-nance patterns in chronic hepatitis delta determine early responseto interferon alpha therapy[J]. J Viral Hepat, 2018, 25 (11) :1384-1394.
    [41] URBAN S. Liver capsule:Entry and entry inhibition of hepatitis Bvirus and hepatitis delta virus into hepatocytes[J]. Hepatology, 2016, 63 (2) :633.
    [42] TAVANEZ JP, CUNHA C, SILVA MC, et al. Hepatitis delta virus ri-bonucleoproteins shuttle between the nucleus and the cytoplasm[J]. RNA, 2002, 8 (5) :637-646.
    [43] SHELDON J, RAMOS B, TORO C, et al. Does treatment of hepa-titis B virus infection reduce hepatitis delta virus replication in HIV-HBV-HDV coinfected patients?[J]. Antiviral Ther, 2008, 13 (1) :97-102.
    [44] REIJNDERS JG, RICKBORST V, SONNEVELD MJ, et al. Kineticsof hepatitis B surface antigen differ between treatment withpeginterferon with and entecavir[J]. J Hepatol, 2011, 54 (3) :449-454.
    [45] HEIDRICH B, YURDAYD C, KABAAM G, et al. Late HDV RNArelapse after peginterferon alpha-based therapy of chronic hepa-titis delta[J]. Hepatology, 2014, 60 (1) :87-97.
    [46] YURDAYDIN C, BOZKAYA H, ONDER FO, et al. Treatment ofchronic delta hepatitis with lamivudine vs. lamivudine+interferonvs. interferon[J]. J Viral Hepat, 2008, 15 (4) :314-321.
    [47] LANFORD RE, GUERRA B, CHAVEZ D, et al. GS-9620, an oralagonist of Toll-like receptor-7, induces prolonged suppressionof hepatitis B virus in chronically infected chimpanzees[J]. Gas-troenterology, 2013, 144 (7) :1508-1517.
    [48] ELAZAR M, GLENN JS. Emerging concepts for the treatment ofhepatitis delta[J]. Curr Opin Virol, 2017, 24:55-59.
    [49] HUANG J, PANG XQ, XIE DY. Role of DNA recognition receptorsin pathogenic mechanism of hepatitisB[J]. J Clin Hepatol, 2017, 33 (9) :1794-1797. (in Chinese) 黄劲, 庞秀青, 谢冬英. DNA识别受体在乙型肝炎发病机制中的作用[J].临床肝胆病杂志, 2017, 33 (9) :1794-1797.
    [50] WINER BY, SHIRVANI-DASTGERDI E, BRAM Y, et al. Preclinicalassessment of antiviral combination therapy in a genetically hu-manized mouse model for hepatitis delta virus infection[J]. SciTransl Med, 2018, 10 (447) :eaap9328.
    [51] YURDAYDIN C, IDILMAN R, KALKAN R, et al. A phase 2 dose-optimization study of Lonafarnib with Ritonavir for the treatment ofchronic delta hepatitis-end of treatment results from the LOWRHDV-2 study[J]. J Hepatol, 2017, 66 (1) :33-34.
    [52] BAZINET M, PANTEA V, CEBOTARESCU V, et al. Update on thesafety and efficacy of REP 2139 monotherapy and subsequentcombination therapy with pegylated interferon alpha-2a in Cauca-sian patients with chronic HBV/HDV coinfection[J]. J Hepatol, 2016, 64 (2) :s584-s585.
  • 期刊类型引用(10)

    1. 李晏杰,王娜,王沙,唐鲲,毛德文,石清兰,龙富立. HBV相关性肝衰竭发病中的Th细胞免疫调控机制及中医药干预的研究进展. 内蒙古中医药. 2023(11): 134-138 . 百度学术
    2. 霍瑞静,张翠丽,李静,何晨熙,李帅,高健. NF-κB信号通路对慢性乙型肝炎患者Th17/Treg相关细胞因子水平变化的影响. 中华医院感染学杂志. 2022(17): 2570-2573 . 百度学术
    3. 黄杏,刘文志,陈斌. 清温并用法治疗肝衰竭的中医理论及作用机制探讨. 中国医学创新. 2021(10): 164-167 . 百度学术
    4. 陈斌,丁秀丽,彭杰,黎运芳,王若宇,周意. 清温并用法对慢加急性肝衰竭肠源性内毒素血症大鼠结肠组织FoxP3, ROR-γt表达的影响. 中国实验方剂学杂志. 2020(02): 19-25 . 百度学术
    5. 谭年花,陈斌,彭杰,朱文芳,张涛,周意,王若宇. 乙肝相关性慢加急性肝衰竭“阳黄-阴阳黄-阴黄”不同证候分型患者Treg/Th17的表达. 中国实验方剂学杂志. 2020(02): 33-38 . 百度学术
    6. 陈斌,黎运芳,张涛,朱文芳,彭杰,张茜茜. 清温并用法对慢加急性肝衰竭大鼠肝组织Treg/Th17型细胞因子及转录因子的影响. 中华中医药杂志. 2020(09): 4618-4622 . 百度学术
    7. 李薇,于佳卉,王新婷,王春梅,李贺,陈建光,孙靖辉. 北五味子总木脂素对环磷酰胺诱导的免疫功能低下小鼠的调节作用. 吉林大学学报(医学版). 2019(02): 294-299+472 . 百度学术
    8. 陈斌,彭杰,张涛,朱文芳,张茜茜,丁秀丽,黎运芳. 清温并用法对慢加急性肝衰竭大鼠结肠组织调节性T淋巴细胞/辅助性T淋巴细胞17细胞因子的影响. 湖南中医药大学学报. 2019(05): 573-577 . 百度学术
    9. 张龙跃,张序瑞. 赤芍解毒汤保留灌肠治疗慢加急性肝衰竭临床研究. 系统医学. 2019(13): 138-140 . 百度学术
    10. 梁琼,赵隽,苏静,梁琳,张吉发. 凉血化瘀解毒法对急性肝衰竭模型大鼠免疫功能、Toll样受体及VEGF表达的影响. 中国中医急症. 2019(10): 1700-1704 . 百度学术

    其他类型引用(5)

  • 加载中
计量
  • 文章访问数:  1618
  • HTML全文浏览量:  85
  • PDF下载量:  332
  • 被引次数: 15
出版历程
  • 收稿日期:  2018-09-18
  • 出版日期:  2019-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回